[ad_1]
Original title: Dynamics of the global epidemic: the number of confirmed cases exceeds 50.91 million. WHO says the vaccine will only become popular in 2021. Source: Financial Associated Press
Statistics released by Johns Hopkins University in the United States show that at 11:25 p.m. on November 10, Beijing time, the number of confirmed cases of new coronary pneumonia worldwide rose to 50,913,451, of which 1,263,089 deaths .
(Overview of the global epidemic, source: Johns Hopkins University)
The number of new confirmed cases in the United States has remained above 100,000 in a single day. A total of 10,110,552 confirmed cases of new coronary pneumonia have been reported and 238,251 patients have died.
The new wave of epidemics in Europe is not yet under control. At press time, a total of 1,856,292 cases have been confirmed in France, 1,381,218 cases in Spain, 1,216,747 cases in the United Kingdom, 960,373 cases in Italy, and 689,146 cases in Germany.
Among the major emerging market countries, India (8,591,730 cases), Brazil (5,675,032 cases) and Russia (1,781,997 cases) are severely affected. The outbreaks in Argentina (1,250,499 cases), Colombia (1,149,064 cases), Mexico (967,825 cases) and Peru (922,333 cases) are not optimistic.
The following is the daily trend of recently confirmed cases in the relevant countries:
(Source: Finance Association, Wind)
Epidemic dynamics
[El Secretario de Salud de EE. UU. Espera que la nueva vacuna de la corona esté disponible para el público la próxima primavera]
According to media reports, US Health Secretary Alex Azar said Tuesday that there may be enough new corona vaccines for the public to vaccinate in the spring. Speaking about the vaccine distribution schedule from Pfizer or other companies, Azar said that by the end of January next year, there will be enough vaccines available for nursing homes and medical personnel, and they will be available nationwide in early January. April.
[QUIÉN: Las vacunas no serán populares hasta 2021]
The World Health Organization’s new coronavirus special envoy, Nabarro, said Tuesday that just a new coronavirus vaccine is not enough. Pfizer’s vaccine report is good news, but it may take several months to provide the vaccine until 2021.
[El número de muertos en Corea del Sur después de que la vacunación contra la influenza supera los 100]
According to a report by the Korean Agency for Disease Control on the 10th, more than 12.56 million people were vaccinated against influenza and 101 deaths after vaccination, most of whom were elderly. The Korean Agency for Disease Control said that after analyzing 97 deaths, it is believed that it has nothing to do with vaccination against influenza; another 4 deaths are being investigated. Recently, many places in South Korea have reported deaths after influenza vaccination, which has caused controversy in public opinion. However, the South Korean government has stated many times that no deaths have been found to be significantly related to vaccination and will continue to promote vaccination work across the country.
[Pfizer puede suministrar 120 millones de dosis de la nueva vacuna corona a Japón para junio del próximo año]
Regarding the supply of the new coronavirus vaccine developed by Pfizer, a major US pharmaceutical company, to Japan, Pfizer Japan has proposed a policy that if it obtains a clinical trial license in Japan, it will be supplied to Japan. January to June 2021. 120 million doses of vaccine. Pfizer has reached an agreement with the Japanese government. It is estimated that Pfizer vaccines will need to be vaccinated twice per person. According to a rough estimate, the supply mentioned above can be used to vaccinate 60 million people.
[El nuevo anticuerpo corona de Lilly obtiene autorización de uso de emergencia en los Estados Unidos]
At the 9th local time, the US Food and Drug Administration (FDA) authorized the emergency use right of the new corona-neutralizing antibody bamlanivimab (LY-CoV555) developed by Eli Lilly. 700 mg of bamlanivimab will be administered through a single intravenous injection and will be allowed for use in patients with mild to moderate COVID-19 older than 12 years.
Market performance
On Tuesday, the three major US stock indices mixed, and technology stocks continued to lead the decline. As of press time, the S&P 500 Index fell 0.88%, the Nasdaq Index fell 2.30% and the Dow Jones Index rose 0.13%. Most of the major European stock indices rose.
(Source: Investing)
